ReviewCurrent therapeutic research, clinical and experimental2026
Efficacy of Orlistat on Cardiometabolic Indices in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A GRADE-Assessed Systematic Review and Meta-Analysis of RCTs.
Review in Current therapeutic research, clinical and experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to cardiometabolic abnormalities. Orlistat has demonstrated potential benefits on metabolic parameters, yet its efficacy in MASLD remains unclear. This meta-analysis aimed to assess the effects of Orlistat on cardiometabolic indices in patients with MASLD. Methods: To identify relevant randomized controlled trials (RCTs), a comprehensive search was conducted across major databases from inception to January 2026. Outcomes assessed included aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), triglycerides (TG), total cholesterol (TC), low- and high-density lipoprotein cholesterol (LDL-C, HDL-C), fasting blood glucose (FBG), fasting insulin (FI), homeostatic model assessment for insulin resistance (HOMA-IR), body mass index (BMI), systolic and diastolic blood pressure (BP). Pooled effect sizes were calculated using a random-effects model using weighted mean differences (WMD) with 95% confidence intervals (CI). Results: Six RCTs were included in this meta-analysis. The pooled analysis showed that Orlistat significantly improved liver enzymes, with reductions in AST (WMD: -4.01 U/L, 95% CI: -6.05 to -1.97, Conclusion: Orlistat may improve cardiometabolic and liver function in MASLD patients, significantly reducing liver enzymes, enhancing lipid profiles, improving glycemic control, and lowering BMI. These results indicate its potential as an effective therapeutic option for metabolic management. However, larger, high-quality RCTs with longer follow-up are necessary to confirm its long-term efficacy and safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.